X4 Pharmaceuticals

XFOR

Market cap $324M

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals, Inc. (XFOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, XFOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR's 4WARD Phase 3 trial in CN will be key. This could unlock a sizeable TAM across 15,000 patients with moderate-to-severe symptoms. Mavorixafor's initial Phase 2 data showed that once-daily oral doses helped with ANC and may reduce G-CSF exposure.

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston. The X4 team will hold a fireside chat on November 10th at 8:30 a.m.

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $5.41 per share a year ago.

Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings Successful completion of two financial transactions totaling $240.3M; cash runway now extends to the end of 2028 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update. “The third quarter of 2025 was a time of corporate restructuring at X4 with the start of a new leadership team and a renewed focus on chronic neutropenia,” said Adam Craig, M.D.

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 6,984,000 additional shares, at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering were approximately $155.3 million before deducting underwriting discounts and commissions and other offering expenses payable by X4. The total shares outstanding after giving effect to the offering was 79,214,708. All of the securities were offered by X4.

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering are expected to be approximately $135 million before deducting underwriting discounts and commissions and other offering expenses payable by X4, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on October 27, 2025, subject to the satisfaction of customary closing conditions. In addition, X4 has granted the underwriters an option for a period of 30 days to purchase up to an additional 6,984,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by X4.

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, X4 expects to grant the underwriters an option for a period of 30 days to purchase up to a number of additional shares of common stock equal to 15% of the shares of common stock and pre-funded warrants initially offered at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by X4.

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.